Skip to main content
. 2019 Jul 10;17:220. doi: 10.1186/s12967-019-1959-3

Fig. 1.

Fig. 1

Comparison of overall survival (OS) and disease-free survival (DFS) according to DNMT3A R882 status in AML patients. a, b Impact of DNMT3A R882 mutations on OS (a) and DFS (b) in AML patients. c, d Impact of DNMT3A R882 mutant types on OS (c) and DFS (d) in AML patients. e, f Impact of allele ratio of DNMT3A R882 mutation on OS (e) and DFS (f) in AML patients